Member Info for Fruitsnveg

That’s funny.

That’s great news.

Yes I'd add US entities to that list, public or private. SNG have indicated that they will seek financing this year, or next year. Either, or. They have cash until 2026. This is only 2024. The use case for Synairgen strengthens with every bit of (related /IFN) new research data coming out, and it keeps coming.

Personally, I would read that as normal pre-deal language. The last thing you want to signal to entities on the opposite side of the Board table is a willingness to be taken for a ride. "If it comes about" means it has to be in the interests of the BOD representing shareholders. No deal is better than a bad deal, as they say...

Unsurprising I think, given it's expected to be used as a (continuous) maintenance treatment. Costs will inevitably mount up with treatment over an extended period.

There most definitely are a number of non-dilutive funding options available; I've been saying it for months, as have others. Just a cursory read back through editions of 'Endponts' publications online will give you a a flavour for the array of funding options available. Mutually beneficial deals are not rare anymore, it's just some posters on here prefer to ignore them and not research them, as it does not serve their narrative.

Dipffs raises a very valid point about the trial structure in the recent report. Here's what the company said: "Preparatory work for a trial commenced in 2023 and has continued into 2024. The company is currently

finalising potential trial structures and a potential financing plan to enable it to pursue an enhanced trial structure. If this comes about, details will be communicated in due course.". For sure, the traditional clinical trial model is now longer an optimum route in this new age of precision medicine, which Synairgen are clearly aligned to. After all, the first dozen or so pages in their 2023 AGM report was pretty much just about precision medicine. Adaptive trials/platform trials / phenotyping - all words we are no aware of and link to enhanced trial design. Here is an article - worth a read - explaining how much cancer clinical trials are transforming from old P1,2,3 models, to using enhanced trial designs : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693060/

Finally, I think one would be misinformed to assume many investors have gone because they have lost faith and put any stock in some of the wilder claims made here. Based on what I know of a number of PI's, that is a false assumption with no basis in fact.

I think there will be a door in and out. My guess is there will be no need to climb through a window.

Word of the day is ‘bang-a-bonk’ (19th century): to sit lazily on a river bank and forget the world for a while.

Sounds good to me. Who’s in?

Going, going, gong.

It's hard to take someone that names themselves after Bobby Axelrod and Capital radio seriously. Very hard.

10,770 posts on one company Manifesto.

Agenda much?

No incorrect. He continued with his launching his COPD app while he consulted/investigated for Synairgen on previous trials. And studies for other bios. And UOS professorshiping. He continued his many other roles at the same time. He’s a capable chap, used to multitasking. Perfectly normal in this field.

Ghia

A couple of corrections to your misinformed post:

TW was never a contractor - he’s a consultant. Subtle but material difference. He was also a lead investigator, as were a number of others , who like him, have fully paid up day jobs and other consulting relationships.

He has been involved in and spearheaded many separate pulmonary-related initiatives for years. He was never exclusively providing services to Synairgen, ever.

People close to the company are doing other things. As expected. No idea why you find this confounding.

Finally, how do you know they haven’t provided retainers or have agreements in place that will allow them access, assuming that is even necessary in the future? Has someone from the company told you that? If not there’s no basis for that claim.

Maybe they have their sights on the US instead of the UK. Prof Wilko works lives in Southampton UK, last time I checked.

"paper trail of clues"

Lol. Not exactly standing up to scrutiny though are they? Eats, shoots, runs away. Hardly the 2ndcoming.

Where's Ghia though.?

He keeps avoiding my questions.

Why? I'm surely not the only one who values his opinion?

“They force you to be like them—or else you’re their enemy.”

― John Irving, The World According to Garp

Someone has to. All this negative noddy chit chat sends me into a stupor if I’m honest….

Yawn, Spac.

“ If they don't RNS until Friday - it'll be bad news.”

The world according to Garp.

I mean DocDan.